LONDON–(BUSINESS WIRE)–The global
bacterial vaginosis (BV) drugs market is expected to grow at
a CAGR of more than 2% during the forecast period, according to
Technavio’s latest report.
In this report, Technavio
covers the market outlook and growth prospects of the global bacterial
vaginosis drugs market for 2017-2021. The market is segmented based on
ROA, which includes oral and topical and geography, which includes the
Americas, EMEA, and APAC.
The global BV drugs market belongs to the wide spectrum of global
infectious disease therapeutics market. The global infectious disease
therapeutics market can be broadly divided into several sub-markets with
the BV drugs market being one of them. The rising awareness about
women’s health and wellness and advent of new drugs such as VivaGel BV
is expected to foster the growth of the global BV drugs market.
and life sciences research analysts categorize the global
bacterial vaginosis drugs market into the following segments by regions:
Looking for more information on this market? Request
a free sample report
Technavio’s sample reports are free of charge and contain multiple
sections of the report including the market size and forecast, drivers,
challenges, trends, and more.
Americas: largest bacterial vaginosis drugs market
The Americas dominated the global BV
drugs market with a market share of almost 42% in 2016. The US was
the largest revenue contributor, capturing a significant portion of the
market. This is due to the high investment in the healthcare segment in
the US. Apart from the US, Canada, Brazil, and Mexico are expected to be
significant contributors in the BV drugs market.
“High prevalence rate of the indication in the female population of
the region is expected to act as a driver for the BV drugs market in the
region. BV is the most common type of vaginal infection affecting women
aged between 15-44 years of age. BV is also highly prevalent in pregnant
women. It is expected that around 15% of the pregnant women in the US
suffer from BV,” says Sapna Jha, a lead analyst at Technavio for
research on infectious
and rare diseases.
This report is available at a USD 1,000 discount for a limited time
market snapshot before purchasing
Buy 1 Technavio report and get the second for 50% off. Buy 2
Technavio reports and get the third for free.
Bacterial vaginosis drugs market in EMEA
The growing awareness regarding women’s health and established
healthcare infrastructure in Europe have led demand of BV drugs market
in the region. The developed economies of Europe such as the UK, Italy,
Spain, Germany, and France hold the major share of the market in the
“The growing product approvals are expected to fuel the market growth
in EMEA. For instance, VivaGel BV by Starpharma Holdings received
marketing approval in the European Union for rapid relief of BV in
September 2015,” adds Sapna.
Bacterial vaginosis drugs market in APAC
APAC is one of the most attractive regions for the BV drugs market. This
is majorly due to the rising healthcare expenditure by the developing
economies such as India and China. Also, China is one of the fastest
growing pharma markets and is expected to lead the BV drugs market in
the region. The growth is attributed to the investment by the government
in the healthcare sector.
However, providing adequate healthcare facilities to large population
residing below the poverty line is a huge challenge for these countries.
Also, low awareness rate regarding the women health is a huge constraint
hindering the growth of the BV drugs market in the region.
The top vendors in the global bacterial vaginosis drugs market
highlighted in the report are:
- Starpharma Holdings
Browse Related Reports:
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team